PE20170687A1 - Proteinas de enlace a cd127 - Google Patents
Proteinas de enlace a cd127Info
- Publication number
- PE20170687A1 PE20170687A1 PE2017000247A PE2017000247A PE20170687A1 PE 20170687 A1 PE20170687 A1 PE 20170687A1 PE 2017000247 A PE2017000247 A PE 2017000247A PE 2017000247 A PE2017000247 A PE 2017000247A PE 20170687 A1 PE20170687 A1 PE 20170687A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- amino acid
- acid sequence
- refers
- chain variable
- Prior art date
Links
- 102000023732 binding proteins Human genes 0.000 title 1
- 108091008324 binding proteins Proteins 0.000 title 1
- 150000001413 amino acids Chemical group 0.000 abstract 4
- -1 AMINO Chemical class 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 108010038498 Interleukin-7 Receptors Proteins 0.000 abstract 1
- 102000010782 Interleukin-7 Receptors Human genes 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
SE REFIERE A UN ANTICUERPO HUMANIZADO QUE COMPRENDE: A) UNA REGION VARIABLE DE CADENA PESADA QUE COMPRENDE LAS SIGUIENTES REGIONES DETERMINANTES DE COMPLEMENTARIEDAD i) CDRH1 CON UNA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 2, ii) CDRH2 CON UNA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 3, Y iii) CDRH3 CON UNA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 4, O 132 A 137; Y B) UNA REGION VARIABLE DE CADENA LIGERA QUE COMPRENDE LAS SIGUIENTES REGIONES DETERMINANTES DE COMPLEMENTARIEDAD iv) CDRL1 CON UNA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 5, v) CDRL2 CON UNA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 6, Y vi) CDRL3 CON UNA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 7. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHO ANTICUERPO SE ENLAZA AL RECEPTOR DE IL-7 HUMANO (CD127) SIENDO UTIL EN EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES TAL COMO ESCLEROSIS MULTIPLE
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29901010P | 2010-01-28 | 2010-01-28 | |
| PCT/US2011/022507 WO2011094259A2 (en) | 2010-01-28 | 2011-01-26 | Cd127 binding proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170687A1 true PE20170687A1 (es) | 2017-06-13 |
Family
ID=44320081
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012001071A PE20121702A1 (es) | 2010-01-28 | 2011-01-26 | Proteinas de enlace cd127 |
| PE2017000247A PE20170687A1 (es) | 2010-01-28 | 2011-01-26 | Proteinas de enlace a cd127 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012001071A PE20121702A1 (es) | 2010-01-28 | 2011-01-26 | Proteinas de enlace cd127 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9150653B2 (es) |
| EP (1) | EP2528947A4 (es) |
| JP (1) | JP5850860B2 (es) |
| KR (1) | KR20130028055A (es) |
| CN (1) | CN102812046B (es) |
| AR (1) | AR080027A1 (es) |
| AU (1) | AU2011209713B2 (es) |
| BR (1) | BR112012018914A2 (es) |
| CA (1) | CA2787070A1 (es) |
| CL (1) | CL2012002081A1 (es) |
| CO (1) | CO6592067A2 (es) |
| CR (1) | CR20120404A (es) |
| EA (1) | EA023700B1 (es) |
| IL (1) | IL220899A (es) |
| MA (1) | MA34004B1 (es) |
| MX (1) | MX339083B (es) |
| MY (1) | MY160590A (es) |
| NZ (1) | NZ601271A (es) |
| PE (2) | PE20121702A1 (es) |
| PH (1) | PH12012501549A1 (es) |
| SG (1) | SG182590A1 (es) |
| TW (1) | TWI489996B (es) |
| UA (1) | UA104663C2 (es) |
| UY (1) | UY33202A (es) |
| WO (1) | WO2011094259A2 (es) |
| ZA (1) | ZA201205624B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3604339B1 (en) | 2011-01-14 | 2021-03-10 | The Regents Of The University Of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
| EP2583980A1 (en) * | 2011-10-19 | 2013-04-24 | Effimune | Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates |
| EP2955196A1 (en) | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
| EP3207061A1 (en) | 2014-10-18 | 2017-08-23 | Pfizer Inc | Anti-il-7r antibody compositions |
| CN107427577A (zh) | 2015-03-31 | 2017-12-01 | 韦斯夸尔德有限公司 | 具有蛋白酶可切割接头的肽构建体 |
| JP2018511346A (ja) | 2015-03-31 | 2018-04-26 | ブイエイチスクエアード リミテッド | ポリペプチド |
| WO2017055966A1 (en) | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
| WO2017120479A1 (en) * | 2016-01-07 | 2017-07-13 | The Schepens Eye Research Institute, Inc. | Therapeutics for ocular immunoinflammatory diseases |
| ME03446B (me) | 2016-02-29 | 2020-01-20 | Ose Immunotherapeutics | Ne-antagonistička antitela usmerena protiv alfa lanca ekstracelularnog domena il7 receptora i njihova upotreba u lečenju kancera |
| MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| MA49727B1 (fr) * | 2016-12-09 | 2021-05-31 | Ose Immunotherapeutics | Anticorps et polypeptides dirigés contre cd127 |
| MA51583A (fr) * | 2018-01-04 | 2020-11-11 | Avidity Biosciences Inc | Molécules d'acide nucléique hétéroduplex et leurs utilisations |
| EP3914622A1 (en) * | 2019-01-22 | 2021-12-01 | Bristol-Myers Squibb Company | Antibodies against il-7r alpha subunit and uses thereof |
| WO2020254827A1 (en) | 2019-06-21 | 2020-12-24 | Vhsquared Limited | Polypeptides |
| AU2020295767A1 (en) | 2019-06-21 | 2022-02-17 | Sorriso Pharmaceuticals, Inc. | Compositions |
| US20220242945A1 (en) | 2019-06-21 | 2022-08-04 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| CN110894237B (zh) * | 2019-12-05 | 2021-08-03 | 山东省分析测试中心 | 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用 |
| GB2595299B (en) | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
| US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
| CN119301276A (zh) | 2022-05-30 | 2025-01-10 | Ose免疫疗法 | Il7r调节剂活性的生物标志物 |
| EP4572772A1 (en) | 2022-08-17 | 2025-06-25 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| EP4646225A1 (en) | 2023-01-06 | 2025-11-12 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
| EP4646274A1 (en) | 2023-01-06 | 2025-11-12 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
| EP4455308A1 (en) | 2023-04-24 | 2024-10-30 | Les Laboratoires Servier | Il-7r gene signatures |
| WO2024249954A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025098341A1 (en) * | 2023-11-10 | 2025-05-15 | Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. | IL-7Ra TARGETING ANTIBODIES AND USES THEREOF |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025202213A1 (en) | 2024-03-26 | 2025-10-02 | Institut National de la Santé et de la Recherche Médicale | Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US20040049014A1 (en) * | 1988-12-28 | 2004-03-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| WO1990015870A1 (en) | 1989-06-15 | 1990-12-27 | Immunex Corporation | Interleukin-7 receptors |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6800738B1 (en) * | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| DE69229477T2 (de) | 1991-09-23 | 1999-12-09 | Cambridge Antibody Technology Ltd., Melbourn | Methoden zur Herstellung humanisierter Antikörper |
| GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| DE69308573T2 (de) | 1992-08-17 | 1997-08-07 | Genentech Inc | Bispezifische immunoadhesine |
| ATE183513T1 (de) | 1993-06-03 | 1999-09-15 | Therapeutic Antibodies Inc | Herstellung von antikörperfragmenten |
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| US5795737A (en) | 1994-09-19 | 1998-08-18 | The General Hospital Corporation | High level expression of proteins |
| US6129913A (en) * | 1994-12-23 | 2000-10-10 | Smithkline Beecham Corporation | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| IL126772A0 (en) * | 1996-05-04 | 1999-08-17 | Zeneca Ltd | Monoclonal antibody of cea conjugates comprising said antibody and their therapeutic use in an adept system |
| PL335050A1 (en) | 1997-02-07 | 2000-03-27 | Merck & Co Inc | Synthetic genes gag hiv |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9806530D0 (en) | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Inflammatory mediator |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2366514C (en) * | 1999-04-13 | 2009-09-15 | Manfred Schmitt | Diagnostic and therapeutic use of antibodies against the urokinase receptor |
| AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
| ATE448301T1 (de) | 2000-09-08 | 2009-11-15 | Univ Zuerich | Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten |
| CN1671416B (zh) | 2001-07-12 | 2013-01-02 | 杰斐逊·富特 | 超人源化抗体 |
| NZ571596A (en) | 2001-08-03 | 2010-11-26 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| EP2042517B1 (en) | 2002-09-27 | 2012-11-14 | Xencor, Inc. | Optimized FC variants and methods for their generation |
| WO2004063351A2 (en) | 2003-01-09 | 2004-07-29 | Macrogenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
| US20050025763A1 (en) * | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| CA2531238C (en) | 2003-07-04 | 2015-02-24 | Affibody Ab | Polypeptides having binding affinity for her2 |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| CN1946417A (zh) | 2003-12-05 | 2007-04-11 | 阿德内克休斯治疗公司 | 2型血管内皮生长因子受体的抑制剂 |
| JP2008512353A (ja) | 2004-07-21 | 2008-04-24 | グライコフィ， インコーポレイテッド | 主にＧｌｃＮＡｃ２Ｍａｎ３ＧｌｃＮＡｃ２グリコフォームを含むイムノグロブリン |
| WO2006052660A2 (en) * | 2004-11-04 | 2006-05-18 | Childrens Hospital Los Angeles Research Institute | Il-7 receptor blockade to suppress immunity |
| KR20150004933A (ko) * | 2006-12-18 | 2015-01-13 | 제넨테크, 인크. | 항-ｎｏｔｃｈ3 길항제 항체 및 ｎｏｔｃｈ3-관련 질환의 예방 및 치료에 있어서 그의 용도 |
| EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
| CN101977937A (zh) * | 2008-01-22 | 2011-02-16 | 拜奥根Idec马萨诸塞公司 | Ron抗体及其用途 |
| TW201018482A (en) | 2008-08-08 | 2010-05-16 | Glaxo Wellcome Mfg Pte Ltd | Novel treatment |
-
2011
- 2011-01-26 PH PH1/2012/501549A patent/PH12012501549A1/en unknown
- 2011-01-26 CN CN201180015856.0A patent/CN102812046B/zh not_active Expired - Fee Related
- 2011-01-26 AU AU2011209713A patent/AU2011209713B2/en not_active Ceased
- 2011-01-26 KR KR1020127022553A patent/KR20130028055A/ko not_active Abandoned
- 2011-01-26 US US13/574,847 patent/US9150653B2/en not_active Expired - Fee Related
- 2011-01-26 NZ NZ601271A patent/NZ601271A/en not_active IP Right Cessation
- 2011-01-26 AR ARP110100251A patent/AR080027A1/es unknown
- 2011-01-26 UY UY0001033202A patent/UY33202A/es not_active Application Discontinuation
- 2011-01-26 MY MYPI2012003394A patent/MY160590A/en unknown
- 2011-01-26 MX MX2012008765A patent/MX339083B/es active IP Right Grant
- 2011-01-26 CA CA2787070A patent/CA2787070A1/en not_active Abandoned
- 2011-01-26 MA MA35147A patent/MA34004B1/fr unknown
- 2011-01-26 JP JP2012551247A patent/JP5850860B2/ja not_active Expired - Fee Related
- 2011-01-26 PE PE2012001071A patent/PE20121702A1/es not_active Application Discontinuation
- 2011-01-26 PE PE2017000247A patent/PE20170687A1/es not_active Application Discontinuation
- 2011-01-26 WO PCT/US2011/022507 patent/WO2011094259A2/en not_active Ceased
- 2011-01-26 US US13/013,993 patent/US8940303B2/en not_active Expired - Fee Related
- 2011-01-26 EP EP11737543.6A patent/EP2528947A4/en not_active Withdrawn
- 2011-01-26 UA UAA201209254A patent/UA104663C2/ru unknown
- 2011-01-26 BR BR112012018914A patent/BR112012018914A2/pt not_active IP Right Cessation
- 2011-01-26 SG SG2012053138A patent/SG182590A1/en unknown
- 2011-01-26 TW TW100102962A patent/TWI489996B/zh not_active IP Right Cessation
- 2011-01-26 EA EA201290589A patent/EA023700B1/ru not_active IP Right Cessation
-
2012
- 2012-07-12 IL IL220899A patent/IL220899A/en not_active IP Right Cessation
- 2012-07-24 CO CO12124175A patent/CO6592067A2/es active IP Right Grant
- 2012-07-25 ZA ZA2012/05624A patent/ZA201205624B/en unknown
- 2012-07-26 CL CL2012002081A patent/CL2012002081A1/es unknown
- 2012-07-31 CR CR20120404A patent/CR20120404A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170687A1 (es) | Proteinas de enlace a cd127 | |
| PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
| CO2020014727A2 (es) | Anticuerpo anti proteína reguladora de señales alfa sirpαlfa | |
| PE20142242A1 (es) | Anticuerpos humanos anti-cd27, metodos, y usos | |
| AR086579A1 (es) | Proteinas de union a antigeno | |
| PE20080181A1 (es) | Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimer | |
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| NZ603972A (en) | Anti-fgfr2 antibodies | |
| AR081556A1 (es) | Proteinas de union al antigeno humanizadas | |
| ES2571129T3 (es) | Anticuerpos anti-CTLA4 humanizados | |
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| AR080698A1 (es) | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e | |
| PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| AR072985A1 (es) | Tratamiento para una enfermedad autoinmune o trastorno inflamatorio, procedimiento, anticuerpo, proteina de union | |
| PE20161033A1 (es) | Proteinas de union al antigeno gitr | |
| JP2020500538A5 (es) | ||
| CL2013003140A1 (es) | Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene. | |
| PE20140133A1 (es) | Nuevas proteinas de union a antigenos | |
| PE20141660A1 (es) | PROTEINAS DE UNION A ANTIGENO DE TNF-ALFA CON UNION A FcRn INCREMENTADA | |
| NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
| AR075798A1 (es) | Proteinas de union a il-17 (interleuquina 17) | |
| PE20120554A1 (es) | Polipeptidos y metodo de tratamiento | |
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| PE20130159A1 (es) | Anticuerpos anti-cd40 | |
| NZ623347A (en) | Novel anti-dr5 antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |